| Literature DB >> 29717337 |
Marja A Heiskanen1, Kumail K Motiani1, Andrea Mari2, Virva Saunavaara3,4, Jari-Joonas Eskelinen1, Kirsi A Virtanen3, Mikko Koivumäki1, Eliisa Löyttyniemi5, Pirjo Nuutila1,3,6, Kari K Kalliokoski1, Jarna C Hannukainen7.
Abstract
AIMS/HYPOTHESIS: Pancreatic fat accumulation may contribute to the development of beta cell dysfunction. Exercise training improves whole-body insulin sensitivity, but its effects on pancreatic fat content and beta cell dysfunction are unclear. The aim of this parallel-group randomised controlled trial was to evaluate the effects of exercise training on pancreatic fat and beta cell function in healthy and prediabetic or type 2 diabetic participants and to test whether the responses were similar regardless of baseline glucose tolerance.Entities:
Keywords: Beta cell function; Exercise training; High-intensity interval training; Moderate-intensity continuous training; Pancreatic fat content; Pancreatic metabolism; Prediabetes; Type 2 diabetes
Mesh:
Substances:
Year: 2018 PMID: 29717337 PMCID: PMC6061150 DOI: 10.1007/s00125-018-4627-x
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122
Fig. 1Participant flow diagram. The analyses were carried out using intention-to-treat principle and hence included all the randomised participants. T2DM, type 2 diabetes mellitus
Number of completed experiments in the study
| Variable | Healthy men | Prediabetic or type 2 diabetic participants | ||||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | |||
| Men | Women | Men | Women | |||
| Participants with at least one measurement | 28 | 26 | 16 | 10 | 13 | 8 |
| Pancreatic fat content, completed | 23 | 21 | 12 | 8 | 12 | 6 |
| Pancreatic glucose uptake, completed | 22 | 23 | 14 | 10 | 12 | 7 |
| Pancreatic fatty acid uptake, completed | 23 | 17 | 16 | 8 | 12 | 5 |
| Beta cell function, completed | 28 | 23 | 16 | 10 | 13 | 8 |
Participant characteristics of healthy and prediabetic or type 2 diabetic men and glycaemic control
| Variable | Healthy men | Men with prediabetes or T2DM | |||||
|---|---|---|---|---|---|---|---|
| Pre ( | Post ( | Pre ( | Post ( | Baseline difference | Time | Time × DM | |
| Prediabetic/T2DM participants ( | – | – | 5/11 | 4/9 | |||
| Age (years) | 48 (46, 50) | 49 (48, 51) | 0.14 | ||||
| Weight (kg) | 83.6 (79.7, 87.5) | 83.3 (79.4, 87.2) | 96.3 (91.2, 101.5) | 96.2 (91.0, 101.3) | <0.001* | 0.20 | 0.80 |
| BMI (kg/m2) | 26.1 (25.1, 27.1) | 26.0 (25.0, 27.0) | 30.4 (29.1, 31.8) | 30.4 (29.0, 31.7) | <0.001* | 0.17 | 0.70 |
| Waist circumference (cm) | 95.5 (92.4, 98.6) | 94.8 (91.7, 98.0) | 105.3 (101.0, 109.6) | 104.7 (100.4, 109.0) | <0.001* | 0.018* | 0.84 |
| Fat (%) | 22.6 (20.9, 24.3) | 21.7 (20.0, 23.3) | 28.8 (26.5, 31.2) | 28.1 (25.7, 30.4) | <0.001* | <0.001* | 0.78 |
| Subcutaneous fat (kg)a | 4.09 (3.69, 4.53) | 4.04 (3.64, 4.04) | 5.58 (4.87, 6.41) | 5.52 (4.87, 6.41) | <0.001* | 0.030* | 0.93 |
| Visceral fat (kg)a | 3.05 (2.70, 3.44) | 2.98 (2.64, 3.36) | 4.22 (4.97, 3.59) | 4.08 (4.80, 3.47) | 0.002* | 0.002* | 0.54 |
| 34.2 (32.7, 35.7) | 35.7 (34.2, 37.2) | 29.3 (27.2, 31.4) | 30.0 (27.9, 32.1) | <0.001* | 0.003* | 0.23 | |
| 35.3 (30.0, 40.6) | 38.7 (33.3, 44.1) | 17.5 (10.3, 24.8)) | 21.6 (14.2, 29.0) | <0.001* | 0.007* | 0.80 | |
| HbA1c (mmol/mol) | 36.9 (35.2, 38.6) | 34.8 (33.0, 36.5) | 39.6 (37.3, 41.8) | 37.5 (35.2, 39.9) | 0.071 | <0.001* | 0.87 |
| HbA1c (%) | 5.5 (5.4, 5.7) | 5.3 (5.2, 5.5) | 5.8 (5.6, 6.0) | 5.6 (5.4, 5.8) | 0.080 | <0.001* | 0.90 |
| Fasting glucose (mmol/l)b | 5.5 (5.3, 5.7) | 5.7 (5.5, 6.0) | 7.2 (6.9, 7.6) | 7.1 (6.8, 7.5) | <0.001* | 0.26 | 0.086 |
| Fasting insulin (pmol/l)b | 4.8 (3.9, 6.0) | 6.0 (4.7, 7.5) | 14.5 (10.9, 19.3) | 13.6 (10.0, 18.5) | <0.001* | 0.37 | 0.11 |
| Fasting NEFA (mmol/l) | 0.70 (0.62, 0.77) | 0.62 (0.54, 0.70) | 0.69 (0.60, 0.78) | 0.68 (0.58, 0.78) | 0.86 | 0.072 | 0.15 |
| OGTT 2 h glucose (mmol/l) | 5.8 (5.0, 6.6) | 6.0 (5.1, 6.8) | 11.2 (10.1, 12.2) | 10.3 (9.2, 11.4) | <0.001* | 0.16 | 0.058 |
| OGTT 2 h insulin (pmol/l)b | 26.8 (21.2, 33.9) | 27.3 (21.2, 35.1) | 66.9 (49.4, 90.7) | 64.4 (46.0, 90.0) | <0.001* | 0.93 | 0.82 |
| OGTT glucose AUC (mmol/l × min) | 845 (774, 916) | 887 (812, 961) | 1342 (1250, 1435) | 1323 (1225, 1421) | <0.001* | 0.67 | 0.25 |
Results are mean (95% CI) for age. For all other variables, the results are model-based means (95% CI)
The baseline difference p value indicates whether there is a baseline difference between healthy and prediabetic or type 2 diabetic men. The time p value displays the mean change between pre- and post-measurements. The Time × DM p value indicates whether the mean changes are different between healthy and prediabetic or type 2 diabetic men
aSquare root transformation performed
bLogarithmic transformation (log10) performed
*p ≤ 0.05
DM, diabetes mellitus; T2DM, type 2 diabetes mellitus
Fig. 2Pancreatic fat content in healthy and prediabetic or type 2 diabetic men at baseline (a), before and after the training intervention when participants were grouped into healthy and prediabetic or type 2 diabetic men (b), and before and after the training intervention when men were grouped according to low (≤6.2%) and high (>6.2%) pancreatic fat at baseline (c). The shaded area in (a) denotes normal pancreatic fat content (≤6.2%). (b, c) Square root transformation was performed to calculate model-based means and 95% CI. Circles, healthy men; squares, prediabetic men; triangles, type 2 diabetic men; white symbols, before exercise intervention; black symbols, after exercise intervention. T2DM, type 2 diabetes mellitus. *p ≤ 0.05, ***p ≤ 0.001 for baseline difference between the groups; †p ≤ 0.05 for time effect; ‡‡‡p ≤ 0.001 time effect for men with high pancreatic fat content
Correlations between pancreatic fat content and whole-body and beta cell variables in all men
| Variable | Pancreatic fat content (%) | |||
|---|---|---|---|---|
| Baseline, all men | Changes, all men | |||
|
|
|
|
| |
| BMI (kg/m2) | 0.42 | 0.012* | 0.28 | 0.30 |
| Fat (%) | 0.45 | 0.007* | 0.05 | 0.81 |
| Visceral fat (kg) | 0.59 | <0.001* | 0.19 | 0.33 |
| −0.28 | 0.12 | −0.20 | 0.36 | |
| HbA1c (mmol/mol) | 0.18 | 0.30 | −0.30 | 0.14 |
| Fasting glucose (mmol/l) | 0.35 | 0.040* | −0.11 | 0.60 |
| Fasting insulin (pmol/l) | 0.28 | 0.10 | −0.11 | 0.59 |
| Fasting NEFA (mmol/l) | −0.28 | 0.13 | −0.08 | 0.71 |
| Pancreatic glucose uptake (μmol 100 g−1 min−1) | −0.12 | 0.55 | 0.23 | 0.28 |
| Pancreatic fatty acid uptake (μmol 100 g−1 min−1) | −0.18 | 0.33 | −0.02 | 0.93 |
| ISRbasal (pmol min−1 m−2) | 0.41 | 0.015* | −0.06 | 0.77 |
| ISRearly (nmol/m2) | 0.18 | 0.30 | −0.21 | 0.32 |
| ISRtotal (nmol/m2) | 0.42 | 0.014* | −0.10 | 0.63 |
| Glucose sensitivity (pmol min−1 m−2 [mmol/l]−1) | −0.14 | 0.41 | −0.02 | 0.92 |
| Rate sensitivity (pmol m−2 [mmol/l]−1) | 0.06 | 0.75 | −0.05 | 0.82 |
| Potentiation factor ratio | −0.26 | 0.14 | 0.10 | 0.62 |
*Statistically significant p value (p ≤ 0.05)
Pancreatic metabolism and beta cell function in healthy and prediabetic or type 2 diabetic men
| Variable | Healthy men | Prediabetic/T2DM men | |||||
|---|---|---|---|---|---|---|---|
| Pre ( | Post ( | Pre ( | Post ( | Baseline difference | Time | Time × DM | |
| Pancreatic metabolism | |||||||
| Glucose uptake (μmol 100 g−1 min−1) | 3.9 (3.6, 4.2) | 4.0 (3.7, 4.3) | 3.7 (3.3, 4.1) | 3.8 (3.4, 4.3) | 0.53 | 0.31 | 0.97 |
| Fatty acid uptake (μmol 100 g−1 min−1)a | 1.4 (1.2, 1.6) | 1.2 (1.0, 1.5) | 1.3 (1.0, 1.5) | 1.2 (1.0, 1.5) | 0.46 | 0.38 | 0.54 |
| Beta cell function | |||||||
| ISRbasal (pmol min−1 m−2) | 81 (69, 94) | 89 (76, 102) | 152 (136, 169) | 139 (122, 157) | <0.001* | 0.54 | 0.006* |
| ISRearly (nmol m−2)b | 7.5 (6.4, 8.7) | 9.1 (7.7, 10.7) | 9.1 (7.4, 11.1) | 8.5 (6.9. 10.6) | 0.15 | 0.23 | 0.028* |
| ΔISR0–30/ΔG0–30 (nmol m−2/mmol l−1)b | 0.16 (0.13, 0.19) | 0.12 (0.10, 0.15) | 0.08 (0.06, 0.10) | 0.07 (0.05, 0.09) | <0.001* | 0.010* | 0.71 |
| ISRlate (nmol/m2) | 32 (28, 36) | 32 (28, 36) | 41 (36, 46) | 41 (36, 47) | 0.005* | 0.98 | 0.85 |
| ISRtotal (nmol/m2) | 40 (36, 45) | 42 (37, 46) | 50 (45, 56) | 50 (44, 56) | 0.008* | 0.75 | 0.65 |
| Glucose sensitivity (pmol min−1 m−2 [mmol/l]−1) | 114 (94, 133) | 114 (94, 133) | 61 (35, 86) | 58 (31, 84) | 0.001* | 0.81 | 0.81 |
| Rate sensitivity (pmol m−2 [mmol/l]−1) | 1043 (836, 1250) | 842 (620, 1065) | 726 (453, 1000) | 452 (156, 748) | 0.12 | 0.013* | 0.69 |
| Potentiation factor ratioa | 2.0 (1.7, 2.4) | 1.9 (1.6, 2.3) | 1.3 (1.0, 1.7) | 1.7 (1.3, 2.2) | 0.010* | 0.29 | 0.086 |
Results are presented as model-based means (95% CI)
The baseline difference p value indicates whether there is a baseline difference between healthy and prediabetic or type 2 diabetic men. The Time p value displays the mean change between pre- and post-measurements. The Time × DM p value indicates whether the mean changes are different between healthy and prediabetic or type 2 diabetic men
aSquare root transformation performed
bLogarithmic transformation (log10) performed
*Statistically significant p value (p ≤ 0.05)
DM, diabetes mellitus; T2DM, type 2 diabetes mellitus
Fig. 3ISR (a) and potentiation (b) during 2 h OGTTs in healthy and prediabetic or type 2 diabetic men before and after the training intervention. The shaded area in (a) denotes ISRearly (0–30 min), which increased only in healthy men (p = 0.006 for the time effect in healthy men). There were non-significant differences in the potentiation of insulin secretion between prediabetic or type 2 diabetic men and healthy men (p = 0.083 for time effect for the potentiation factor ratio in prediabetic or type 2 diabetic men). White circles, healthy men before the exercise intervention; black circles, healthy men after the exercise intervention; white squares, prediabetic or type 2 diabetic men before the exercise intervention; black squares, prediabetic or type 2 diabetic men after the exercise intervention